T A B L E O F C O N T E N T S

Data collection and analysis
Two review authors screened the results of the searches against inclusion criteria, extracted data and assessed risk of bias independently and in duplicate. We used mean differences (MDs) and 95% confidence intervals (CIs) for continuous data and risk ratios (RRs) with 95% CIs for dichotomous data. Meta-analyses would have been undertaken using a random-effects model if the number of studies had exceeded a minimum of three. Study authors were contacted where possible and where deemed necessary for missing information.
Main results
A total of 3239 citations were identified through the searches. Only one RCT, with 15-year follow-up met the inclusion criteria (n = 13 clusters: 191,873 participants). There was no statistically significant difference in the oral cancer mortality rates for the screened group (15.4/100,000 person-years) and the control group (17.1/100,000 person-years), with a RR of 0.88 (95% CI 0.69 to 1.12). A 24% reduction in mortality was reported between the screening group (30/100,000 person-years) and the control group (39.0/100,000) for high-risk individuals who used tobacco or alcohol or both, which was statistically significant (RR 0.76; 95% CI 0.60 to 0.97).
No statistically significant differences were found for incidence rates. A statistically significant reduction in the number of individuals diagnosed with stage III or worse oral cancer was found for those in the screening group (RR 0.81; 95% CI 0.70 to 0.93). No harms were reported. The study was assessed as at high risk of bias.
Authors' conclusions
There is evidence that a visual examination as part of a population-based screening programme reduces the mortality rate of oral cancer in high-risk individuals. In addition, there is a stage shift and improvement in survival rates across the population as a whole. However, the evidence is limited to one study, which has a high risk of bias and did not account for the effect of cluster randomisation in the analysis. There was no evidence to support the use of adjunctive technologies like toluidine blue, brush biopsy or fluorescence imaging as a screening tool to reduce oral cancer mortality. Further RCTs are recommended to assess the efficacy and cost-effectiveness of a visual examination as part of a population-based screening programme in low, middle and high-income countries.
P L A I N L A N G U A G E S U M M A R Y
Screening programmes for the early detection and prevention of oral cancer
Review question
This review, carried out by authors of the Cochrane Oral Health Group, was conducted to investigate the effectiveness of current screening programmes in detecting oral cancer at an early stage and whether or not they can assist in decreasing deaths due to oral cancer.
Background
Oral cancer is increasing worldwide and it is the sixth most common cancer overall. The highest rates of oral cancer occur in the most disadvantaged sections of the population. Important risk factors in the development of the disease are tobacco, alcohol, age, gender and sunlight although a role for candida (which causes thrush) and the human papillomavirus (which causes warts) has also been documented. People who are heavy drinkers and also smoke have 38 times the risk of developing oral cancer compared with people who do neither. These factors are considered to be especially important in the development of the disease in young people, a group experiencing an increasing incidence of the disease, particularly in countries with a high incidence of it.
Geographic variation in the occurrence of oral cancer around the world is wide. For example it is the most common cancer for men in India, Sri Lanka and Pakistan and 30% of all new cases of cancer in these countries is oral cancer whereas only 3% of new cases of cancer in the United Kingdom are oral cancer.
When people first seek medical help, their oral cancer is usually at a late or advanced stage and the effects of the condition as well as the treatment for it can be extremely debilitating. Death rates from oral cancer and the negative effects of the disease are high and increasing rather than declining as for other cancers such as breast and colon.
Prevention screening programmes for other cancers have proven to be effective in early detection. However, whilst there maybe advantages to screening there are disadvantages because screening has the potential to produce either false positive or false negative results. Screening can be targeted at high-risk groups, it can be opportunistic, for example when people attend health services for other reasons, or can be done by looking at statistics across the population as a whole.
The aim of preventive screening for early detection of oral cancer is to screen individuals for pre-cancerous conditions which are lesions such as leukoplakia. The most common screening method is visual inspection by a clinician but other techniques include the use of a special blue dye, the use of imaging techniques and measuring biochemical changes to normal calls.
Study characteristics
The evidence on which this review is based is up to date as of 22 July 2013. The only study included was based in rural areas of the city of Trivandrum in Kerala, India. The study included 191,873 apparently healthy adults aged 35 years or older living in 13 clusters with an average of 14,759 participants in each cluster. Screening took place in seven clusters (96,517 participants) and six clusters acted as a control (95,356 participants). Participants were excluded if they were bedridden, if they had open tuberculosis, other debilitating diseases or were already suffering from oral cancer.
Healthcare workers trained in the detection of oral lesions undertook the screening of participants and the social history of participants including use of paan, tobacco, alcohol and dietary supplements was recorded.
Key results
The review found that overall there is not enough evidence to decide whether screening by visual inspection reduces the death rate for oral cancer and there is no evidence for other screening methods. However, there is some evidence that it might help reduce death rates in patients who use tobacco and alcohol although the only included study may be affected by bias.
Quality of evidence
The evidence presented is of low quality and limited to one study assessed as at high risk of bias.
B A C K G R O U N D
Description of the condition
Oral cancer is the sixth most common cancer globally and represents a group of conditions with a range of sites and a varied aetiology. Its annual estimated incidence is approximately 275,000, but unlike many other cancers, its incidence is increasing (Warnakulasuriya 2009). There is a wide geographic variation in the incidence of the disease with two-thirds of the burden born by low-income and middle-income countries from South and SouthEast Asia, Latin America and Eastern Europe. However, the incidence continues to rise in the West (IARC 2010) and the age standardised incidence of oral cancer in Western Europe has steadily increased over the past two decades (Boyle 2005) . Within the European Union countries, the highest male incidence rates are found in France and Hungary, whilst the lowest rates are found in Greece and Cyprus (IARC 2010) . India, Sri Lanka and Pakistan have the highest levels of disease, making it the most common cancer for men in these countries and accounts for up to 30% of all new cases of cancer compared to 3% in the United Kingdom (UK) and 6% in France (Cancer Research UK). The age-adjusted incidence rate from these countries cancer registries range from 3.4 to 13.8 per 100,000 (Ogden 2005) , although the precise mechanism remains unclear (Ogden 1998 
Description of the intervention
Prevention strategies are important to meet the World Health Organization's (WHO) resolution to incorporate oral cancer into national cancer control programs (Petersen 2009). Although it is important to continue to clarify the public health message and promote primary prevention, determining the feasibility of a national screening programme is an important step in the prevention of the disease. The National Screening Committee define screening as "a process of identifying apparently healthy people who may be at increased risk of a disease or condition" (NSC 2010). Screening can be undertaken across the whole population, opportunistically, when individuals are attending for some other purpose, or selectively, where high-risk groups are targeted. Programmes for major cancers, such as breast, cervical and bowel cancer have effectively improved the mortality rates and helped to decrease the incidence of these cancers (Gøtzsche 2006; Hewitson 2007) . However, it is important to consider both the harms and benefits of any screening programmes. For example, screening for breast cancer has recently been associated with over-diagnosis and unnecessary treatment causing further physical and psychological harms (Gøtzsche 2013) and so any future programme should always balance these considerations.
How the intervention might work
Screening is predicated on the idea that malignancy is preceded by clinically evident lesions, which if identified early and removed, can either prevent their malignant transformation or reduce their staging. 
Why it is important to do this review
The RCT provides the strongest level of evidence on which to base clinical decisions (Clarkson 2003) and so represents a level of rigor that is appropriate for assessing the effectiveness of any intervention or programme. As with other cancers, screening for oral cancer and PMDs has potential advantages and disadvantages (Speight 1992 
O B J E C T I V E S
To assess the effectiveness of current screening methods in decreasing oral cancer mortality.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of screening programmes for the early detection of oral cancer or potentially malignant disorder (PMD), which report on the associated mortality rates subsequent to the screen.
Types of participants
Participants involved in population, selective (high-risk) or opportunistic screening programmes were included.
Types of interventions
Any health technology used in a screening programme for the detection of oral cancer or PMD:
• visual screening;
• visual staining using toluidine blue;
• oral cytology using brush biopsies;
• fluorescence imaging and light-based techniques.
As this was not a diagnostic test accuracy review, the definition of a positive case in each of these categories was not defined; each study was assessed on an individual study-by-study basis.
Types of outcome measures
The primary outcome measure for this review was oral cancer mortality.
Other outcomes included were:
• incidence of oral cancer or PMD;
• stage at diagnosis;
• adverse effects (outcomes from false positive or false negative results, if known);
• cost data (where reported).
Search methods for identification of studies Electronic searches
For the identification of studies included or considered for this review, detailed search strategies were developed for each database searched. These were based on the search strategy developed for MEDLINE (OVID) but revised appropriately for each database (Appendix 1). The search strategies for MEDLINE and CAN-CERLIT used a combination of controlled vocabulary and free text terms. 
Databases searched
We searched the following electronic databases.
• The Cochrane Oral Health Group's Trials Register (to 22 July 2013) (Appendix 2).
• CENTRAL (The Cochrane Library 2013, Issue 6) (Appendix 3).
• MEDLINE via OVID (1946 to 22 July 2013) (Appendix 1).
• EMBASE via OVID (1980 to 22 July 2013) (Appendix 4).
• CANCERLIT via PubMed (1950 to 22 July 2013) (Appendix 5).
Searching other resources
The following journals were handsearched for this review to 2010:
• Oral Oncology • 
Language
There were no non-English papers that required translation. Had such trials been identified they would have been translated through The Cochrane Collaboration.
Unpublished trials
The bibliographies of included papers and relevant review articles were checked for studies not identified by the search strategies above. The authors of identified and included studies were also contacted to identify unpublished or ongoing trials.
Data collection and analysis
Selection of studies
The titles and abstracts obtained from initial electronic searches were scanned for relevance independently by two of the review authors (Paul Brocklehurst (PRB), Anne-Marie Glenny (AMG)). Reports from the studies that fulfilled the inclusion criteria were obtained. When there was insufficient data in the study title to determine whether a study fulfilled the inclusion criteria, the full report was obtained and assessed independently by the same review authors. Disagreement was resolved by discussion.
Data extraction and management
All studies meeting the inclusion criteria underwent data extraction and an assessment of risk of bias was made. Studies rejected at this and subsequent stages were recorded in the table of excluded studies. Data from each included study was extracted independently using the tool developed and reported in Kujan 2005. Differences were again resolved by discussion. If a single publication reported two or more separate studies, then each study was extracted separately. If the findings of a single study were spread across two or more publications, then the publications were extracted as one. For each study with more than one control or comparison group for the intervention, the results were extracted for each intervention arm. For each trial the following data were recorded.
• Year of publication, country of origin and source of study funding.
• Details of the participants including demographic characteristics and criteria for inclusion.
• Details on the type of intervention and comparisons.
• Details on the study design.
• Details on the outcomes reported, including method of assessment.
Assessment of risk of bias in included studies
Assessment of risk of bias was conducted by three review authors (PRB, AMG, Lucy O'Malley (LO)) using the Cochrane risk of bias assessment tool. The domains that were assessed for each included study were: sequence generation, allocation concealment, blinding, completeness of outcome data, risk of selective outcome reporting and risk of other potential sources of bias. A description of the domains was tabulated for each included trial, along with a judgement of the risk of bias in accordance with the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (Higgins 2011). A summary assessment of the risk of bias across all the domains for each study was then undertaken (Higgins 2011).
• Low risk of bias -a low risk of bias for all key domains.
• Unclear risk of bias -an unclear risk of bias for one or more key domains.
• High risk of bias -a high risk of bias for one or more key domains.
Measures of treatment effect
For dichotomous outcomes, the estimate of effect was expressed as risk ratios with 95% confidence intervals; for continuous outcomes, mean differences were used with 95% confidence intervals.
Unit of analysis issues
The analysis for cluster randomised trials was undertaken, when feasible, at the same level of randomisation, or at an individual level with the effect of clustering being accounted for.
Assessment of heterogeneity
The significance of any discrepancies in the estimates of the treatment effects from the different trials was assessed by means of Cochran's test for heterogeneity, considered statistically significant at the level of P value < 0.1 (Higgins 2011). The percentage total variation across the included studies was used to quantify heterogeneity and expressed as I 2 , with a value over 50% representing substantial heterogeneity (Higgins 2011).
Assessment of reporting biases
Publication bias would have also been assessed using funnel plot asymmetry (Higgins 2011).
Data synthesis
Meta-analyses would have been undertaken if the number of trials had exceeded a minimum of three. Risk ratios would have been combined for dichotomous data, and mean differences for continuous data using a random-effects model, if data had allowed.
R E S U L T S Description of studies
A total of 3239 citations were identified through the MED-LINE searches. The full text of 30 articles were retrieved. Following further screening, 26 of these were excluded with reasons (Characteristics of excluded studies). One of the excluded studies did undertake a community-based randomised controlled trial to examine the efficacy of toluidine blue in Taiwan (Su 2010). However, the primary aim was to determine whether toluidine blue enhanced the detection rate for potentially malignant disorders (PMD), not mortality rate. Although they did link the examined cohort with the National Cancer Registry to determine five-year follow-up, the power calculation was based on the former not the latter. As a result, the study was excluded from this review but included in an accompanying diagnostic test accuracy review (Walsh 2013). Only one study (four reports) met the inclusion criteria (Sankaranarayanan 2000) . The principal investigator of the included trial (Dr Sankaranarayanan) was also contacted and no other relevant trials were identified (Figure 1 ).
The included study (Trivandrum Oral Cancer Screening Study; Sankaranarayanan 2000) was designed to have an 80% power at the 5% significance level to detect a 35% reduction in the cumulative mortality rate of oral cancer in 12 years of enrolment between the intervention and the control groups. The study commenced in October 1995 and three rounds of screening at three-year intervals were planned for the study. The first round was completed in May 1998 and the second was completed in June 2002. The third round was completed in October 2004. A final round of screening was completed in 2009. All participants (n = 191,873) were apparently healthy residents aged 35 years or older and lived in 13 rural clusters around Trivandrum City, Kerala, India, The mean number of eligible participants in each cluster was 14,759. These clusters were allocated into an intervention arm (n = 7) and a control arm (n = 6) by a blocked randomisation process. Those residents who were bedridden, suffering from open tuberculosis or other debilitating diseases were excluded alongside those participants who had already been diagnosed with oral cancer prior to entry into the study. In the intervention arm, non-medical university graduates were initially trained and were provided with two simple manuals on oral visual examination with colour photographs and descriptions of various oral lesions. Eligible participants were interviewed and information relating to demographic, social and personal habits including the use of paan, tobacco, alcohol and dietary supplements was recorded. Tobacco and alcohol cessation advice was provided as appropriate. Oral visual inspections were performed in daylight with the help of a flashlight. All the intra-oral sites were carefully examined and palpated and the neck was also palpated to detect enlarged lymph nodes. The findings were recorded as normal, non-referable lesions and referable lesions. Participants who had a positive screen were referred for examination by a dentist or physician for confirmation. It is unclear whether these clinicians were also trained in the recognition of oral cancer or PMDs. Oral biopsies were performed in those with clinically confirmed homogeneous leukoplakias, non-homogeneous leukoplakias, oral submucous fibrosis and oral cancers. Surgical excision was undertaken for leukoplakia wherever possible. All PMDs were reviewed regularly. In the control arm, participants were visited by a "control health worker" who recorded the same sociodemographic information and measured height, weight, blood pressure and respiratory peak flow measurements. The health workers in the control arm were not trained to undertake a visual oral inspection. Oral cancer mortality was reported as the main outcome measure. Of the 96,517 eligible subjects in the intervention arm, 25,144 (26.1%) had one, 22,382 (23.2%) had two, 22,008 (22.8%) had three and 19,288 (20.0%) had four cycles of screening. 49,179 (51.0%) individuals were screened in the first round and 55,993 (58.0%), 64,898 (67.2%) and 43,014 (44.6%) were screened in the second, third and fourth cycles respectively. The participation rate (at least one screen) for this group was 88,822 (92%); males (86%) and females (94%). Of the 95,356 eligible subjects in the control group, 43,992 (46.1%) were screened in the fourth cycle. Demographic details were not provided for the final (fourth) cycle of screening, but were provided for the first three cycles (Additional Table 2 ). Across the period of the study (all four cycles), 6.3% (n = 5586) of subjects screened as part of the intervention group had a referable lesion and 59% (n = 3298) of these screen positive subjects complied with referral (Additional Table 3 ). The control group consisted of 95,356 persons. 46% (n = 43,992) of the control group were screened in the final (fourth) cycle and 2.6% (n = 1163) of these were found to have a referable lesion with 16.3% (n = 189) complying with referral.
Risk of bias in included studies
Allocation Sequence generation
The randomisation procedure was conducted using restricted block randomisation. The exact detail of this process was not provided, although the clusters were grouped into blocks of four and allocated at random to screening or non-screening groups from the six possible combinations available to each block of four. Clustering was not accounted for in the analysis.
Allocation concealment
No detail of allocation concealment was provided, although the principal investigator confirmed that this was not undertaken.
Blinding Blinding of outcome assessment
No blinding was undertaken in the study, but the review authors judge that the outcome and its measurement are unlikely to be influenced by this. As a result, the risk of bias based on the lack of blinding is considered to be low.
Incomplete outcome data
Withdrawals and drop-outs were not described clearly and missing data will have increased the risk of bias. Of those who were referred with positive lesions, 59% of individuals in the screening group complied with referral and 16% in the control group (Additional Table 3 ). The analysis was carried out on an intention-to-treat (ITT) basis.
Selective reporting
The study protocol was not made available, but it appears that the published reports include all the expected and pre-specified outcome measures.
Other potential sources of bias
Positive cases were referred to dentists and physicians to make a diagnosis, but it is unclear whether standardised criteria were used by these clinicians or whether they had received any formal training. It is stated that subjects with confirmed oral cancer and PMDs were biopsied and those with confirmed oral cancer were referred. However, this detail was absent and only 26.4% and 26.0% of subjects with a PMD had a biopsy in the second or third cycle respectively. It is not clear whether all suspected oral cancer cases did receive a biopsy, but given the definition of "interval cases" in the third paper, it would appear not. In addition, it is stated in the third paper that the reference investigation for final diagnosis was clinical examination by physicians or histology or both. As it is not possible to diagnose early malignancy by visual appearance alone, this may have led to substantial under-reporting of oral cancer. The lack of a histological diagnosis for many of the PMDs also makes it difficult to accurately assess the correct diagnosis and true prevalence of these disorders. Prevalence of PMDs is provided in detail for the first two cycles only. The fourth paper presents incidence and mortality data for each round of screening. Neither the third or fourth papers present data regarding prevalence of PMDs. In the included study the health workers reported on 24 baseline variables including multiple age strata, occupation, education, income, household belongings such as television and personal habits of chewing, smoking, and drinking. The intervention and control cohorts appear to have been well matched for the stratified variable age at the baseline. However, the distribution of income, education, use of tobacco and alcohol varied across the intervention and control groups, with the former demonstrating higher levels of consumption (Additional Table 2 ). Men smoked and drank alcohol more than females in both groups, but the prevalence of chewing tobacco was not as marked across gender differences. Although, such differences in baseline variables might be expected to occur in cluster randomised studies, the differences between the numbers who used tobacco and alcohol need to be borne in mind when interpreting the results.
Effects of interventions
The included study reported data on oral cancer incidence, diseasespecific mortality, and stage at diagnosis after 15-years follow-up. Data on quality of life and all cause mortality were not reported.
Oral cancer mortality
There was a 12% reduction in oral cancer mortality between the intervention and control arms, but this difference was not statistically significant. Over the four cycles (15 years), 138 of 279 subjects with oral cancer in the intervention group and 154 of the 244 cases in the control group died, which represents a mortality rate of 15.4 and 17.1 per 100,000 person-years respectively (risk ratio (RR) 0.88; 95% confidence interval (CI) 0.69 to 1.12). Ageadjusted rates were 18.9 per 100,000 person-years in the intervention group and 19.7 per 100,000 person-years in the control (Additional Table 4 ). There was a 24% reduction in oral cancer mortality between the intervention and control arms for those participants who used tobacco or alcohol or both and this difference was statistically significant. Over the four cycles (15 years), 129 of 254 subjects with oral cancer in the intervention group and 147 of the 232 cases in the control group died, which represents a mortality rate of 30.0 and 39.0 per 100,000 person-years respectively (RR 0.76; 95% CI 0.60 to 0.97) (Additional Table 5 ). Age-adjusted rates were 29.1 per 100,000 person-years in the intervention group and 37.1 per 100,000 person-years in the control (Additional Table  4 ). Although data presented after four cycles (15 years) were not divided by gender, the three-year cycle data (nine years) showed a significant reduction of 43% in mortality rates for men from 42.9 per 100,000 person-years in the control group to 24.6 per 100,000 person-years in the intervention group. For women, there was a 22% reduction, from 50.7 to 39.4 per 100,000 person-years, but this did not reach significance. For the participants that adhered to all four cycles of the screening programme, there was a 79% reduction in oral cancer mortality (81% amongst the users of tobacco or alcohol or both) compared to the control, which was statistically significant (Additional Table  6 ).
Oral cancer incidence
Among the 96,517 participants screened in the intervention group, 5586 (6.3%) were found to have referable lesions. Of these, 3298 (59%) complied with the referral criteria for confirmatory examination by dentists or medical officers in special clinics. Healthy mucosa or benign lesions were found in 770 (23.3%). The number of PMDs was 2336 (70.8%) (lichen planus (n = 53), homogenous leukoplakia (n = 898) and submucous fibrosis (n = 573)) and growths suspicious of oral cancer 192/3298 (4%). Of those diagnosed with PMDs, 21.4% (n = 499), underwent biopsies and 4.4% (n = 22) were confirmed squamous cell carcinoma. Of those diagnosed with suspicious growths, 84.9% (n = 163) were confirmed as squamous cell carcinoma and 1.6% (n = 3) as verrucous carcinoma. The detection rate of PMD and oral cancer in the first, second, and third and fourth rounds of screening were 28.0, 11.9, 11.6 and 3.9 per 1000 screened subjects respectively. The crude incident rate of oral cancer was 31.2 per 100,000 person-years in the screening group and 27.2 per 100,000 person-years in the control group, with a risk ratio of 1.14 (95% CI 0.91 to 1.44). Age-adjusted incidence rates were 37.1 per 100,000 person-years and 30.8 per 100,000 person-years respectively (Additional Table 4 ).
Test performance
Across the four cycles (15 years) of the programme, the reported sensitivity of the visual examination in detecting oral cancer was 67.4% (188/279) (Additional Table 4 ). No information on the specificity or the positive predictive value of the programme was recorded.
Survival
Survival rates were calculated by comparing the proportion of patients alive at five years after diagnosis across the two groups. A significantly higher five-year survival rate was reported in the screened group (55.5%) compared to the control (43.4%) (P value = 0.003).
Stage shift at diagnosis
There was a statistically significant stage shift in the cancers that were diagnosed in the screened group, based on the criteria of the International Union Against Cancer/American Joint Committee on Cancer (UICC/AJCC). In the screened group, 147/279 (52.6%) cases were in stage III or worse at diagnosis, as opposed to 159/244 (65.2%) of cases in the control group (RR 0.81; 95% CI 0.70 to 0.93) (Additional Table 4 ; Additional Table 7 ). For users of tobacco, alcohol or both, 138/254 (54.3%) cases were in stage III or worse at diagnosis in the screened group, as opposed to 154/232 (66.4%) of cases in the control group (RR 0.82; 95% CI 0.71 to 0.95) (Additional Table 5 ; Additional Table 7) .
Cost-effectiveness
The costs associated with the screening programme were reported after three cycles (nine years) (Subramanian 2009) (Additional Table 8 ). The benefit produced by a screen was 269.31 life-years saved per 100,000 for all the individuals and 1437.64 for those at high risk. The incremental cost per life-year saved was USD 835 for all individuals, which reduced to USD 156 for high-risk individuals. This fulfils the target set by the World Health Organization (WHO) Commission on Macroeconomics and Health (WHO 2001) , who define an intervention to be cost-effective when its cost-effectiveness ratio is less than a country's gross domestic product per capita. Subramanian argues that this provides good evidence that opportunistic screening of high-risk groups is cost-effective (Subramanian 2009).
D I S C U S S I O N
The incidence of oral cancer is increasing in low, middle and highincome countries (Warnakulasuriya 2009). Delays in diagnosis and management persist (Onizawa 2003; McLeod 2005) and are associated with a dramatic deterioration in five-year survival rates. Effective primary and secondary prevention strategies are critical in delivering the World Health Organization's (WHO) resolution that oral cancer should be an integral part of national cancer control programmes (Petersen 2009).
Given that the majority of oral carcinomas are preceded by visible lesions (Scully 2009), determining the efficacy and effectiveness of screening warrants attention, whilst balancing the potential benefits with any potential negative consequences of any programme (Wilson 1968).
Summary of main results
The study reported a sensitivity of the visual examination in detecting oral cancer was 67.4%. However, the data for users of tobacco, alcohol or both demonstrated a reduction in mortality rates of 24% after four cycles (15 years), which was statistically significant. In addition, there was a statistically significant difference in the number of stage III cancers between the intervention and control arms, suggesting that the screening programme was identifying cancers at an early stage. When these results are combined with the significant stage shift and survival rate in the intervention group, it would appear that visual examination could be effective at reducing mortality rates for oral cancer when used within a targeted screening programme. However, the included study had a high risk of bias.
Overall completeness and applicability of evidence
The purpose of health care is to improve both the quantity and quality of life (Kaplan 2005) . The evidence from the Kerala trial (Sankaranarayanan 2000) is that visual screening can reduce the mortality rate in users of tobacco, alcohol or both and can produce a stage shift. Given that late stage disease is recognised as a major contributory factor for cancer survival (Onizawa 2003; McLeod 2005) , it would appear that the screening of high-risk individuals could be warranted. However, the evidence from this study stems from a population with a high incidence of oral cavity cancer, and its applicability to other countries with lower incidence rates is unknown. In addition, the efficacy of the early management of potentially malignant disorders (PMDs) is a controversial area (Holmstrup 2007; Holmstrup 2009 ). Holmstrup argues that even if early lesions are surgically removed, the risk of malignant change can remain as a result of "field change" i.e. the lesion represents only a small area of a wider field of damaged mucosa (Holmstrup 2007; Holmstrup 2009 ). The trial used non-medical university graduates, trained specifically to perform visual inspection of the oral mucosa, with the help of a flashlight. The screening was undertaken in individuals own home, with the health workers going 'door-to-door'. The ability to translate this screening model to other settings is unclear. However, the Kerala study does demonstrate the potential of allied health professionals to screen for oral cancer and PMDs. This is becoming increasingly relevant as more regulators allow patients to directly access allied providers of dental care (oral health practitioners), in addition to the dentist. The cost-effectiveness of the Kerala study was reported after three cycles (nine years) (Subramanian 2009), demonstrating that 1437.64 life-years could be saved per 100,000 high-risk individuals, with an incremental cost per life-year saved of USD 156. According to the authors, this fulfils the target set by the WHO Commission on Macroeconomics and Health, who define an intervention as being cost-effective when its cost-effectiveness ratio is less than a country's gross domestic product per capita. However, these results also need to be read in context of the relative prevalence of the condition and account for the potential problem of compliance; out of the 5586 participants that were screened positive, only 59% (n = 3298) complied with referral. The consideration of both the benefits and harms of screening is an essential component of any programme (Wilson 1968) and is fundamental to the satisfactory introduction of any technology into daily practice (Duffy 2001) . The sensitivity reported in the Kerala study was relatively low (67%). In addition, false positives can have unintended psychological consequences, for example, increasing anxiety and exposing the patient to unnecessary further investigations. However, these could be reduced by careful patient management and by educating screened patients about the positive benefits of screening (Speight 1992) . Recent studies by Brocklehurst, highlighted the need to train general dental practitioners to discuss positive findings (Brocklehurst 2010b ) and the need for standardised criteria to avoid both under and over-referral in clinical practice (Brocklehurst 2010) .
Quality of the evidence
The Kerala study had a number of methodological weaknesses that may have introduced bias. These included a lack of detail about the process of sequence generation to ensure random assignment, no analysis of the impact of clustering on the results and no detail about allocation concealment. In addition, there was no blinding of the outcome assessment and withdrawals and drop-outs were not described. More importantly, only 59% of individuals with screen-positive lesions in the intervention arm complied with referral and it was unclear whether the clinicians who saw these patients followed any standardised criteria. In addition, only 26.4%, 26.0%, and 21.4% of subjects had a biopsy in the second, third cycle or fourth cycle respectively, with no detail being provided from the first cycle. As it is not possible to diagnose early malignancy by visual appearance alone, this may have led to substantial under-reporting of oral cancer and the lack of a histological diagnosis makes it difficult to accurately assess the correct diagnosis and true prevalence of these disorders. It has been argued that the small number of randomised clusters could also produce statistical heterogeneity and the close geographical proximity of the clusters may have led to contamination (Kujan 2005) .
Potential biases in the review process
We conducted a broad search of several databases and placed no restrictions on the language of publication when searching the electronic databases or reviewing reference lists of included studies. All data extraction and risk of bias assessment was conducted in duplicate.
Agreements and disagreements with other studies or reviews
A meta-analysis of visual screening found a weighted and pooled sensitivity of 84.8% (95% confidence interval (CI) 73.0 to 91.9) and specificity of 96.5% (95% CI 93.0 to 98.2) (Downer 2004). However, there was considerable heterogeneity in the studies pooled due to differences in the size of the target populations and it is arguable that a meta-analysis was inappropriate. A more recent review has evaluated the diagnostic accuracy of non-specialist conventional oral examination, vital rinsing, light-based detection, biomarkers and mouth self examination for the identification of individuals with suspected oral squamous cell carcinoma or PMD. Sensitivity values for studies for all tests were varied and relatively imprecise with sensitivity values ranging from 0. adjunctive techniques to the visual examination (Patton 2008) . In another review, Lingen found that the majority of the published studies had employed these techniques on patients who had already received a diagnosis and that they did not improve upon the sensitivity or specificity of the visual examination (Lingen 2008).
A U T H O R S ' C O N C L U S I O N S Implications for practice
The results suggest that there is insufficient evidence to recommend a whole population screening programme for oral cancer. However, the results from the Kerala study suggest that a targeted population approach could reduce the mortality rate and produce a stage shift, but the risk of bias in the included study means that further well-designed randomised controlled trials are necessary to establish the validity of this relationship.
In the meantime, opportunistic visual screening by appropriately trained dentists and oral health practitioners is recommended for all patients and particularly for those who use tobacco, alcohol or both. Systematic examination of the oral cavity by front-line health workers should remain an integral part of their routine for routine recall appointments.
Implications for research
Given the high risk of bias in the study included in this review, a lack of randomised controlled studies associated with adjunctive methods (e.g. brush biopsy, fluorescence imaging) and a lack of understanding of the natural history of oral cancer, further randomised controlled trials are recommended. These should ensure the method of randomisation is accounted for in the analysis, that there is adequate allocation concealment, a standardised intervention and a clear follow-up procedure.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Sankaranarayanan 2000
Methods
Randomised controlled trial, Kerala, India. Interventions Health workers interviewed the eligible subjects to extract specified information. Intervention group: visual examination of the oral mucosa. Control group: follow-up to the end point. The intervention and control cohorts are being followed up by the Trivandrum population-based cancer registry to determine the incidence and stage distribution of invasive oral cancer, treatment given and mortality Outcomes Oral cancer mortality was the major outcome. Further outcome measures were. 1. Participation: defined as "the number of eligible subjects screened as a proportion of the total eligible in the intervention arm". 2. Positivity rate: defined as "the proportion of screened subjects identified with referable lesions". 3. Detection rate: defined as "the number of subjects with lesions detected per 1000 screened subjects in the intervention group". 4. Compliance with referral: defined as "the proportion of screen positive subjects reporting for diagnostic confirmation by dentists or physicians". 5. Sensitivity, specificity, and positive predictive values. 6. Programme sensitivity and specificity: defined as "the number of screen-detected oral cancers as a proportion of the total oral cancers in the intervention group", "the proportion of screen true-negative subjects among the total non-cancer-eligible subjects" and "the number of screen-detected oral cancers as a proportion of total screen positive subjects" respectively. 7. Incidence rate of oral cancers. 8. Characteristics of oral cancers in the study group including: the maximum dimension of lesions, regional lymph node involvement and International Union Against Cancer/ American Joint Committee on Cancer (UICC/AJCC) TNM stage grouping distribution. 9. Case fatality for oral cancer cases diagnosed during the study period: defined as "the number of deaths among the total number of cases" Other bias Unclear risk Positive cases were referred to dentists and physicians to make a diagnosis, but it is unclear whether standardised criteria were used by these clinicians or whether they had received any training in identification of positive lesions It is stated that subjects with confirmed oral cancer and PMDs were biopsied and those with confirmed oral cancer were referred. However, although not detailed in the first cycle, only 26.4% of subjects with a PMD had a biopsy in the second cycle and only 26% in the third cycle. It is not clear whether all suspected oral cancer cases did receive a biopsy, but given the definition of "interval cases" in the third paper, it would appear not. In addition, it is stated in the third paper that the reference investigation for final diagnosis was clinical examination by doctors or histology or both. As it is not possible to diagnose early malignancy by visual appearance alone, this may have led to substantial under-reporting of oral cancer. The lack of a histological diagnosis for many of the PMDs also makes it difficult to accurately assess the correct diagnosis and
Notes
Risk of bias
D A T A A N D A N A L Y S E S
This review has no analyses. Table 1 . Important potentially malignant disorders (PMDs)
A D D I T I O N A L T A B L E S
The following were identified as PMDs by the World Health Organization's Working Group on Oral Cancer (Warnakulasuriya 2007) .
• Leukoplakia.
• Erythroplakia.
• Palatal lesion of reverse cigar smoking.
• Oral lichen planus.
• Oral submucous fibrosis.
• Discoid lupus erythematosus.
• Hereditary disorders such as dyskeratosis congenita and epidermolysis bullosa. 
A P P E N D I C E S Appendix 1. MEDLINE via OVID search strategy
